Notice of Results and Investor Presentation

14 September 2021

Instem plc
(“Instem”)

Notice of Results and Investor Presentation

Investor Presentation: 4.00pm, Monday 27 September
Management will be providing a presentation and hosting an Investor Q&A session on the results and future prospects, as well as the recent acquisition of PDS Pathology Data Systems Ltd on the day of results, at 4.00pm. Investors can sign up for free and add to attend the presentation via the following link: https://www.investormeetcompany.com/instem-plc/register-investor

Questions can be submitted pre-event and at any time during the live presentation via the Investor Meet Company Platform.

Analyst Presentation: 11:30am, Monday 27 September
Management will be hosting a presentation via web conference on the day of the results at 11.30am. Analysts wishing to join should register their interest by emailing instem@walbrookpr.com or by telephoning 020 7933 8780.

For further information, please contact:

Instem plc www.instem.com
Phil Reason, CEO Via Walbrook
Nigel Goldsmith, CFO  
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel  
Alex Bond  
Rachel Hayes  
Wallbrook Financial PR Tel: +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome  
Nicholas Johnson  

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit instem.com.